Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG

Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03219632

Enrollment

Registered

2017-07-17

Start date

2012-06-05

Completion date

2017-05-30

Last updated

2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Left Ventricular Hypertrophy

Brief summary

Assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients

Detailed description

Patients who were diagnosed with left ventricular hypertrophy (LVH) by ECG at the start of the study are followed up at 3-month intervals for 1 year. Increase Fimasartan if blood pressure is not controlled.

Interventions

DRUGFimasartan

Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients who have been treated or not treated with hypertension from 20 to 80 years of age * Patients with electrocardiographic left ventricular hypertrophy (In this study, we define left ventricular hypertrophy if one of the following two criteria is met) 1. RaVL+SV3 \> 20mm(M). 16mm(F) 2. SV1+RV5 or RV6 \> 35mm. * Patients who are taking or expecting Fimasartan

Exclusion criteria

* Patients with unstable angina or myocardial infarction within 3 months * Patients with clinically significant severe valve disease, congenital heart disease, peripheral vascular disease, cerebrovascular disease * Clinically significant severe congestive heart failure patients * Patients with renal dialysis * Clinically significant renal disease patients * Patients with clinically significant hepatic impairment * Patients with a history of alcohol or substance abuse * Patients with hypersensitivity to angiotensin-receptor blocker * Patients needing angiotensin-receptor blocker drugs other than fimasartan * For women, pregnancy, Patients who are breastfeeding or planning to become pregnant * A person who is determined to be inappropriate by the Investigator * Patients participating in other clinical trials

Design outcomes

Primary

Measure	Time frame	Description
The change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG (composite).	1 year	Measurements of changes in baseline at 12 months (change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026